Integer Holdings Co. (NYSE:ITGR) Shares Sold by Earnest Partners LLC

Earnest Partners LLC reduced its holdings in shares of Integer Holdings Co. (NYSE:ITGR) by 0.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,163,381 shares of the medical equipment provider’s stock after selling 8,196 shares during the period. Earnest Partners LLC owned approximately 3.47% of Integer worth $154,171,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Mather Group LLC. increased its holdings in shares of Integer by 304.3% during the fourth quarter. Mather Group LLC. now owns 190 shares of the medical equipment provider’s stock valued at $25,000 after acquiring an additional 143 shares in the last quarter. Lee Danner & Bass Inc. purchased a new stake in Integer during the 4th quarter worth approximately $27,000. R Squared Ltd acquired a new position in Integer during the 4th quarter valued at approximately $44,000. Sterling Capital Management LLC raised its holdings in shares of Integer by 472.9% in the fourth quarter. Sterling Capital Management LLC now owns 338 shares of the medical equipment provider’s stock worth $45,000 after buying an additional 279 shares during the last quarter. Finally, Versant Capital Management Inc lifted its stake in shares of Integer by 98.4% during the fourth quarter. Versant Capital Management Inc now owns 369 shares of the medical equipment provider’s stock worth $49,000 after buying an additional 183 shares during the period. 99.29% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the company. Benchmark decreased their target price on Integer from $150.00 to $140.00 and set a “buy” rating on the stock in a research report on Friday. Raymond James increased their price objective on shares of Integer from $145.00 to $150.00 and gave the company an “outperform” rating in a report on Friday. Truist Financial set a $150.00 target price on shares of Integer in a research note on Friday. StockNews.com lowered shares of Integer from a “hold” rating to a “sell” rating in a research note on Friday. Finally, KeyCorp dropped their price objective on shares of Integer from $154.00 to $145.00 and set an “overweight” rating for the company in a research note on Monday, April 21st. One research analyst has rated the stock with a sell rating, two have given a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $145.56.

Integer Price Performance

NYSE:ITGR opened at $123.39 on Friday. The company has a market capitalization of $4.31 billion, a P/E ratio of 36.72, a P/E/G ratio of 1.72 and a beta of 1.09. The company has a quick ratio of 2.09, a current ratio of 2.95 and a debt-to-equity ratio of 0.62. Integer Holdings Co. has a 52 week low of $104.93 and a 52 week high of $146.36. The stock’s fifty day moving average is $119.58 and its two-hundred day moving average is $130.26.

Integer (NYSE:ITGR) last issued its quarterly earnings data on Thursday, April 24th. The medical equipment provider reported $1.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.27 by $0.04. The firm had revenue of $437.39 million for the quarter, compared to analyst estimates of $428.51 million. Integer had a net margin of 6.92% and a return on equity of 11.65%. Equities analysts expect that Integer Holdings Co. will post 6.01 EPS for the current year.

Integer Company Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.